Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm Invests in Synthonics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Recipharm Invests in Synthonics

Will partner to develop new compounds

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recipharm has made an equity investment in Synthonics Inc. and purchased $2.0 million of stock in the company. A further $2.0 million of stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.

The companies have also entered into a joint development agreement under which Synthonics gains access to Recipharm’s drug development, marketing and manufacturing expertise in exchange for a royalty payment on certain Synthonics compounds. Synthonics has developed a drug delivery technology for metal coordination of pharmaceutical APIs.

Ken Slepicka, chief executive officer of Synthonics, said, “Synthonics is delighted to extend the partnership with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm’s formulation and development teams and expect this agreement and financial support to help us further advance several of our current projects to commercialization.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics